SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 58 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $127,000 | -56.9% | 106,700 | +17.8% | 0.00% | -100.0% |
| Q4 2021 | $295,000 | -61.8% | 90,600 | -47.5% | 0.00% | -50.0% |
| Q3 2021 | $772,000 | -44.7% | 172,700 | -32.6% | 0.00% | -50.0% |
| Q2 2021 | $1,396,000 | -36.9% | 256,100 | -13.4% | 0.00% | -33.3% |
| Q1 2021 | $2,213,000 | -11.6% | 295,800 | +28.2% | 0.01% | -14.3% |
| Q4 2020 | $2,504,000 | +55.5% | 230,800 | +26.7% | 0.01% | +40.0% |
| Q3 2020 | $1,610,000 | -17.1% | 182,100 | -0.1% | 0.01% | -16.7% |
| Q2 2020 | $1,943,000 | +307.3% | 182,300 | +126.7% | 0.01% | +200.0% |
| Q1 2020 | $477,000 | -34.6% | 80,400 | -23.8% | 0.00% | 0.0% |
| Q4 2019 | $729,000 | +107.1% | 105,500 | +177.6% | 0.00% | +100.0% |
| Q2 2019 | $352,000 | -6.1% | 38,000 | -7.3% | 0.00% | 0.0% |
| Q1 2019 | $375,000 | +32.5% | 41,000 | -19.3% | 0.00% | 0.0% |
| Q4 2018 | $283,000 | -57.1% | 50,800 | -8.3% | 0.00% | -50.0% |
| Q3 2018 | $660,000 | -12.7% | 55,400 | -25.1% | 0.00% | 0.0% |
| Q2 2018 | $756,000 | +620.0% | 74,000 | +585.2% | 0.00% | – |
| Q4 2017 | $105,000 | – | 10,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |